CEO Mark Lappe Buys 2.5 Million Shares After Stock Drop, Signaling Insider Confidence in Inhibrx’s Pipeline

Insider Buying Surge Amid a Volatile Market

Mark Lappe, Inhibrx’s chief executive, added roughly 2.5 million shares to his holdings on October 14, 2026, paying a weighted‑average price of about $85. per share. The purchase was executed through the Lappe Family Trust and an immediate‑family trust, bringing his total stake to 745,588 shares—about 5.6 % of the outstanding equity. The deal comes just two days after the company’s stock slipped 8.7 % on the day before, reflecting a broader bearish trend in the healthcare sector and a sharp quarterly decline in the firm’s share price.

What This Means for Investors

The timing of the transaction—coinciding with a sharp intraday drop—can be interpreted in a few ways. First, Lappe’s willingness to buy at a lower valuation signals confidence in Inhibrx’s pipeline, particularly as the company prepares to present Phase 2/3 data for INBRX‑106 and Phase 2 ChonDRAgon results for INBRX‑109 next month. Second, the sizeable trade could provide a psychological boost to the stock, reassuring market participants that the CEO believes the current price understates future upside. However, the lack of a significant social‑media buzz (0 % intensity, neutral sentiment) suggests the market may not yet be primed for a rally, and the current 52‑week low of $28.16 remains a substantial discount to the $155.29 peak.

Lappe’s Historical Buying Pattern

Examining Lappe’s insider filings over the past month shows a consistent pattern of aggressive buying. From September 8 through September 28, he purchased more than 30 million shares at prices ranging from $98 to $112 per share, increasing his stake from 711,443 to 745,588 shares. The cumulative dollar value of these purchases exceeded $3 billion, indicating a strong conviction in the company’s long‑term prospects. Unlike many CEOs, Lappe has not sold any shares in the same period; his holdings have steadily climbed, suggesting a long‑term horizon rather than short‑term speculation.

Implications for the Company’s Future

If the upcoming conference presentations validate Inhibrx’s therapeutic candidates, the company could unlock new valuation multiples, potentially propelling the stock toward its 52‑week high. Lappe’s continued accumulation of shares could also reduce dilution concerns, as the company may rely less on issuing new equity to fund development. On the downside, the current share price volatility and the fact that the company is still clinical‑stage imply that significant capital will remain required; a shortfall could force a capital raise that would dilute existing shareholders.

Bottom Line for Financial Professionals

For investors looking ahead, Lappe’s recent buy‑in is a positive signal of insider confidence, but it should be weighed against the company’s still‑unproven product pipeline and the broader market’s bearish stance on healthcare stocks. Monitoring the next conference presentations and any subsequent earnings guidance will be critical. The CEO’s buying trend, however, provides a tangible indicator that the firm’s leadership believes in a meaningful upside—an element that can help anchor long‑term investors in an otherwise turbulent environment.